Regulation of body length and bone mass by Gpr126/Adgrg6

Peng Sun1,2,*, Liang He1,*, Kunhang Jia1, Zhiying Yue1, Shichang Li2, Yunyun Jin1, Zhenxi Li1, Stefan Siwko3, Feng Xue4, Jiacan Su5, Mingyao Liu1†, Jian Luo6†

Adhesion G protein–coupled receptor G6 (Adgrg6; also named GPR126) single-nucleotide polymorphisms are associated with human height in multiple populations. However, whether and how GPR126 regulates body height is unknown. In this study, we found that mouse body length was specifically decreased in Osx-Cre;Gpr126fl/fl mice. Deletion of Gpr126 in osteoblasts resulted in a remarkable delay in osteoblast differentiation and mineralization during embryonic bone formation. Postnatal bone formation, bone mass, and bone strength were also significantly affected in Gpr126 osteoblast deletion mice because of defects in osteoblast proliferation, differentiation, and ossification. Furthermore, type IV collagen functioned as an activating ligand of Gpr126 to regulate osteoblast differentiation and function by stimulating cAMP signaling. Moreover, the cAMP activator PTH(1–34), could partially restore the inhibition of osteoblast differentiation and the body length phenotype induced by Gpr126 deletion. Together, our results demonstrated that COLIV-Gpr126 regulated body length and bone mass through cAMP-CREB signaling pathway.

INTRODUCTION

G protein–coupled receptors (GPCRs), also termed seven-transmembrane helix receptors, are the largest family of transmembrane proteins and are involved in a wide variety of physiological processes including bone development and remodeling (1). The adhesion GPCR family, with 33 members, is the second largest subgroup of GPCRs. The defining characteristic of the adhesion GPCR family is their extraordinarily large N-terminal extracellular domain featuring various types of subdomains that are generally thought to communicate with the extracellular milieu and mediate their characteristic adhesive functions (1–3). The adhesion GPCR family member Gpr126 has been implicated in an increasing number of developmental defects. Multiethnic genome-wide association studies and human mutation analyses show that variations and mutations at the GPR126 locus are associated with multiple skeletal defects, including shortened height (4), adolescent idiopathic scoliosis (AIS) (5), arthrogryposis multiplex congenita (6), and periodontitis (7). In genetic studies of experimental animals, it has been reported that Gpr126 deletion in chondrocytes caused idiopathic scoliosis and pectus excavatum (PE), suggesting that Gpr126 in cartilage is the genetic cause for the pathogenesis of AIS (8). Furthermore, other studies reveal that Gpr126 is essential for myelination of axons in the peripheral nervous system (9), as well as in heart (10) and inner ear (11) development in mouse or zebrafish genetic animal models. However, whether GPR126 is a genetic cause for other diseases, including disorders of human height, is largely unknown.

Adhesion GPCRs have been reported to mediate cell–extracellular matrix (ECM) interactions (12). Recently, type IV collagen (COLIV) was reported as an activating ligand for GPR126 in peripheral nerves and inner ear development, and Laminin-211 was described as another previously unidentified GPR126 ligand during Schwann cell development (13, 14). The prion protein is another agonistic ligand for GPR126 in myelination (15). All the reported ligands can induce a GPR126-dependent adenosine 3′,5′-monophosphate (cAMP) response in cells and in animals, suggesting G protein–dependent signaling. Moreover, a peptide sequence (named the Stachel sequence) within the ectodomain of GPR126 can function as a tethered agonist to activate cAMP signaling (16). However, Gpr126 deletion in the chondrocyte lineage caused idiopathic scoliosis without affecting intracellular cAMP signaling, because treating these mice with rolipram, a known cAMP-positive regulator, could not reduce the incidence or severity of idiopathic scoliosis (8), suggesting that GPR126 could use different signaling pathways in different tissues.

Here, we study whether and how GPR126 regulates body height (length), an association that has been established in humans. Our mouse model results indicated that knockout (KO) of Gpr126 in osteoblasts, but not osteoclasts and chondrocytes, led to decreased body length and bone formation. Moreover, COLIV, but not Laminin-211, as an activating ligand of Gpr126, regulated osteoblast differentiation and function by stimulating cAMP signaling but not Wnt/β-catenin signaling. Furthermore, the osteoporosis drug PTH(1–34) [parathyroid hormone (1–34) peptide] could partially rescue the body length and bone mass phenotype induced by Gpr126 deletion in osteoblasts in vivo.

RESULTS

Deletion of Gpr126 in osteoblasts caused a decrease in body length

To examine whether GPR126 regulates body height (length), we used three conditional mouse models (fig. S1). We knocked out Gpr126 in...
the osteoblast lineage (Osx-Cre;Gpr126^fl/fl) (Fig. 1A and fig. S2, A and D), osteoclast lineage (Lysm-Cre;Gpr126^fl/fl) (figs. S2, B and E, and S3A), or chondrocyte lineage (Col2-Cre;Gpr126^fl/fl) (figs. S2, C and F, and S3A). The results showed that only osteoblast-specific Gpr126 KO significantly decreased body length at embryonic (E) day 14.5 (E14.5), E16.5, and E18.5 and at postnatal (P) day P10 and P30 when compared with control littermates (Fig. 1A and fig. S2D). Together, only loss of Gpr126 in the osteoblast lineage, but not the osteoclast or chondrocyte lineages, resulted in a decrease in body length.

Osteoblast-specific Gpr126 deletion delayed embryonic bone formation by regulating osteoblast differentiation in vivo

To investigate how Gpr126 affects body length, we first examined bone development in embryonic mice. We analyzed skeletal preparations stained with Alizarin red for mineralized tissue and Alcian blue for development in embryonic mice. We analyzed skeletal preparations to investigate how Gpr126 deletion delayed embryonic osteoblast-specific chondrocyte lineages, resulted in a decrease in body length. Gpr126 loss of and E18.5 and at postnatal (P) day P10 and P30 when compared with control littermates. To elucidate the role of Gpr126 in regulating bone mass, we analyzed the bone characteristics of mice with Gpr126 deficiency in the osteoblast lineage using micro-computed tomography (μCT). There was a notable decrease of bone mineral density (BMD) and trabecular bone volume in the Osx-Cre;Gpr126^fl/fl mouse femur compared with control littermates, as a consequence of decreased numbers of trabeculae and a reduction in trabecular thickness, while trabecular spacing was increased (Fig. 2, A and B). Next, we investigated whether Gpr126 regulates the mechanical properties of bone. Our results showed that the bone strength (as assessed by maximum load in humerus bones using the three-point bending test) of Osx-Cre;Gpr126^fl/fl mice was remarkably reduced compared to control littermates (Fig. 2D). To examine whether Gpr126 affects the mineralization of vertebral bone, we performed nondecalcified histomorphometric analysis of the vertebral body of Osx-Cre;Gpr126^fl/fl mice and control littermates at P40. We observed that there was a sharp decrease in trabecular bone volume in the Osx-Cre;Gpr126^fl/fl mice compared with control littermates as a consequence of decreased numbers of trabeculae, reduced trabecular thickness, and an increase in trabecular spacing (Fig. 2E). To determine whether the lower bone mass phenotype of the Osx-Cre;Gpr126^fl/fl mice was due to a decrease in bone formation and/or a decrease in osteogenesis, we next performed bone formation rate and osteoid analyses in the vertebral body. The bone formation rate was markedly reduced in Osx-Cre;Gpr126^fl/fl mice by the calcine double labeling assay (Fig. 2F), and osteoid formation including osteoid volume, osteoid surface, and osteoid thickness significantly decreased, as assessed by Goldner’s staining (Fig. 2G). All of the results indicate that Gpr126 regulates bone mass by modulating bone formation and osteoblast mineralization.

Gpr126 deficiency inhibited osteoblast proliferation, differentiation, and mineralization

To examine whether Gpr126 affects BMSC differentiation to osteoblasts, we isolated BMSCs and analyzed osteoblast proliferation, differentiation, and mineralization. Our data showed that Gpr126 deficiency significantly affected the formation of CFU-F (fibroblast colony-forming unit) and CFU-Ob (osteoblast colony-forming unit) colonies (Fig. 3, A and B). Similarly, Gpr126 deletion markedly suppressed osteoblast differentiation and mineralization [measured by alkaline phosphatase (ALP) staining for the differentiation assay, as well as von Kossa staining and Alizarin red staining for the mineralization assay; Fig. 3C]. Furthermore, two osteoblast differentiation markers,
Fig. 1. Body length was decreased and embryonic bone formation was delayed in Osx-Cre;Gpr126<sup>fl/fl</sup> mice. (A) Images of body size at embryonic (E) day 14.5 (E14.5), E16.5, and E18.5 and postnatal (P) day 30 (P30) of Osx-Cre;Gpr126<sup>fl/fl</sup> mice and control (Ctrl) littermates. Scale bars, 5 mm. (B) Whole skeletal preparation of Osx-Cre;Gpr126<sup>fl/fl</sup> mice and Ctrl littermates at E14.5, E16.5, and E18.5. Black arrows indicate the delayed Alizarin red staining (of bone) in the skull, ribs, and phalanges in Osx-Cre;Gpr126<sup>fl/fl</sup> embryos. Scale bars, 5 mm. (C) Body part skeletal preparation of Osx-Cre;Gpr126<sup>fl/fl</sup> mice and Ctrl littermates at E18.5. Black arrows indicate the delayed Alizarin red staining (of bone) in the skull (top), sternum (middle), and phalanges (bottom) in Osx-Cre;Gpr126<sup>fl/fl</sup> embryos. Scale bars, 2 mm. (D) In situ hybridization analysis for expression of osteoblast differentiation markers collagen type I, alpha 1 (Col1a1) (top) and osteocalcin (Ocn) (bottom) in Osx-Cre;Gpr126<sup>fl/fl</sup> and Ctrl littermate femurs at E14.5, E15.5, and E16.5. Red arrows indicate that the signal intensity was decreased in Osx-Cre;Gpr126<sup>fl/fl</sup> embryos. Scale bars, 200 μm. (E) Relative positive area of Col1a1 and Ocn in Osx-Cre;Gpr126<sup>fl/fl</sup> and control littermate femurs at E14.5, E15.5, and E16.5 from in situ hybridization assay. **P < 0.01. n = 2 per group per time point. (F) Von Kossa staining analysis for bone mineralization in E14.5 (left), E16.5 (middle), and E18.5 (right) embryonic femurs of Osx-Cre;Gpr126<sup>fl/fl</sup> and Ctrl littermates. Red arrows indicate that there was no signal at E14.5 in Osx-Cre;Gpr126<sup>fl/fl</sup> embryos. Scale bars, 100 μm (at E14.5, left), 50 μm (at E14.5, right), and 1 mm (at E16.5 and E18.5). Photo credit: Peng Sun, East China Normal University.
Fig. 2. Postnatal bone mass and bone strength were decreased in Osx-Cre;Gpr126fl/fl mice. (A) Representative images of dorsal (top) and lateral (bottom) x-rays of 4-month-old mice (n = 3). Yellow lines indicate that the vertebral column was shorter in Osx-Cre;Gpr126fl/fl mice; yellow arrows indicate the decreased bone density in Osx-Cre;Gpr126fl/fl mice. Scale bars, 2 cm. (B) Representative μCT images of femurs from 1-month-old mice show the proximal femur (top; scale bars, 500 μm) and trabecular bone of the femur metaphysis (bottom; scale bars, 200 μm). (C) Quantitative μCT analysis of trabecular bone parameters of femurs from 1-month-old mice. BMD, bone mineral density; BV/TV, bone-volume/tissue-volume ratio; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness. *P < 0.05, **P < 0.01, ***P < 0.001, n = 5. (D) Maximal loading (Max load) of humeral diaphysis from 1-month-old mice by three-point bending assay. *P < 0.05, **P < 0.01, ***P < 0.001, n = 5. (E) Representative image of von Kossa staining of lumbar sections of 6-week-old mice (top) and trabecular bone parameters (bottom). Scale bars, 500 μm. (F) Bone formation rate was decreased in Osx-Cre;Gpr126fl/fl mice. Representative images of calcein double labeling of the spinal trabecular bone of 6-week-old mice (top). Bone formation parameters from spinal sections of 6-week-old mice (bottom). BFR/BS, bone formation rate per bone surface; MAR, mineral apposition rate. Scale bars, 10 μm. *P < 0.05, **P < 0.01, ***P < 0.001, n = 7. (G) Osteoid formation was suppressed in Osx-Cre;Gpr126fl/fl mice. Representative images of Goldner’s staining of 6-week-old mouse spinal trabecular bone. Spinal bone histomorphometric parameters. Ob.S/BS, osteoblast surface per bone surface; OS/BS, osteoid per bone surface; O.Th, osteoid thickness. Scale bars, 50 μm. *P < 0.05, n = 7.
ALP enzyme activity and Ocn expression, were decreased in Gpr126 deletion cells (Fig. 3D). Therefore, Gpr126 deletion impairs BMSC differentiation to osteoblasts.

**Deletion of Gpr126 suppressed osteoblast differentiation and mineralization by regulating the cAMP-CREB signaling pathway**

Gpr126 is essential for peripheral myelination in Schwann cells (17), angiogenesis by regulating endothelial cell (18), and semicircular canal duct development in the zebrafish inner ear (11), all through the cAMP signaling pathway (19). It is established that, in osteoblastic cells, activation of the cAMP pathway ultimately promotes phosphorylation of the downstream effector CAMP response element–binding protein (CREB) to enhance osteogenic differentiation and mineralization of BMSCs; hence, cAMP-CREB signaling is one of the key pathways to regulate BMSC differentiation into osteoblasts (20). To examine whether Gpr126 regulates osteoblast differentiation and function by the cAMP signaling pathway in osteoblast cells, we measured cAMP concentrations after 14 days of differentiation from BMSCs to osteoblasts. Intracellular cAMP levels were significantly decreased in osteoblast cells from Osx-Cre;Gpr126fl/fl mice (Fig. 4A). Furthermore, phosphorylation of CREB was significantly decreased in Osx-Cre;Gpr126fl/fl mice (Fig. 4B).

To further confirm whether Gpr126 regulates osteoblast differentiation and mineralization by modulation of the cAMP-CREB signaling pathway, we used forskolin (FSK), an activator of adenylyl cyclase, and PTH(1–34), an osteoporosis drug, both of which can induce bone formation and mineralization by promoting cAMP signaling but not Wnt/β-catenin signaling (21). Our results showed that intracellular cAMP levels were decreased in Osx-Cre;Gpr126fl/fl mouse osteoblasts, while FSK substantially increased the intracellular cAMP levels in Osx-Cre; Gpr126fl/fl mouse osteoblast cells (Fig. 4C). As a result, ALP mRNA expression, enzyme activity, Ocn mRNA expression level (Fig. 4D), osteoblast differentiation, and mineralization (Fig. 4E) were rescued in Gpr126 deletion cells upon FSK treatment. Similar results were obtained upon treatment with PTH(1–34) (Fig. 4, F and G). Therefore, Gpr126 signals, at least in part, through cAMP/CREB to regulate osteoblast differentiation and function.

**COLIV regulates osteoblast differentiation and function as an activating ligand of Gpr126 by stimulating cAMP signaling but not Wnt/β-catenin signaling**

It has been previously reported that COLIV, a major structural component of the basement membrane, specifically binds to the extracellular N-terminal region of Gpr126 to stimulate the production of cAMP in some organs including bone (13). Our data showed that COLIV was expressed in both osteoblast and chondrocyte cells (fig. S6). To investigate whether COLIV acts as an activating ligand for Gpr126 and stimulates cAMP production in osteoblasts, we examined the intracellular cAMP levels in osteoblast cells from both Osx-Cre;Gpr126fl/fl mouse and control littermates after stimulating with COLIV. Our results showed that COLIV culture elevated intracellular cAMP concentrations in control osteoblast cells (Fig. 5A), whereas it had little effect on intracellular cAMP levels in Osx-Cre;Gpr126fl/fl osteoblasts. To further confirm COLIV as an activating ligand in osteoblasts, we examined ALP enzyme activity and Ocn mRNA expression, and osteoblast differentiation and mineralization in both Osx-Cre;Gpr126fl/fl mouse and control littermate osteoblast cells stimulated with COLIV. Our results showed that COLIV promoted ALP enzyme activity and Ocn mRNA expression (Fig. 5B), and osteoblast differentiation and mineralization (Fig. 5C) in control osteoblast cells. However, COLIV had little effect on Gpr126 deletion osteoblasts.

Laminin-211 can activate Gpr126 when it is applied under conditions of mechanical force (i.e., vibration); under static conditions, Laminin-211 dose-dependently decreased Schwann cell cAMP levels in a Gpr126-dependent manner (14). Our data showed that, unlike COLIV, Laminin-211 was expressed only in osteoblast cells (fig. S6) and could not activate Gpr126 to regulate osteoblast differentiation and function under static conditions (fig. S7, A to C). Wnt/β-catenin signaling is a key signaling pathway to regulate osteoblast differentiation and function. However, our data showed that the selective Wnt/β-catenin inhibitor KYA1797K has little effect on COLIV-induced osteoblast differentiation and mineralization (fig. S8A). Furthermore, there was no notable difference in Wnt/β-catenin downstream target gene expression when we knocked out Gpr126 in osteoblast cells (fig. S8B). Together, all of our results indicated that COLIV, but not Laminin-211, is an activating ligand of Gpr126 that regulates osteoblast differentiation and maturation by stimulating cAMP signaling, but not Wnt/β-catenin signaling.

**PTH(1–34), but not FSK, rescued the body length and bone mass phenotype induced by osteoblast-specific Gpr126 deletion in vivo**

To further confirm whether FSK or PTH(1–34) could rescue the body length or bone mass phenotype induced by Gpr126 deficiency in osteoblasts, we intraperitoneally injected Osx-Cre;Gpr126fl/fl mice and control littermates daily with FSK (200 μg/kg) or PTH (80 μg/kg) from P5 to P30. The results showed that the body length and femur bone length were restored in Osx-Cre;Gpr126fl/fl mice treated with PTH(1–34) (Fig. 6, A to D). Furthermore, three-dimensional reconstruction of the femur using μCT showed that PTH(1–34) rescued trabecular BMD, trabecular bone volume, the number of trabeculae, and trabecular thickness in Osx-Cre;Gpr126fl/fl mice (Fig. 6, E and F). As a consequence, the maximum load of the tibia bones was rescued in Osx-Cre;Gpr126fl/fl mice when treated with PTH(1–34) (Fig. 6G). However, the other cAMP activator, FSK, had little effect on the body length, femur bone length, and bone mass in Osx-Cre;Gpr126fl/fl mice (fig. S9, A to G). We speculated that this may be due to effects of FSK on other cell types in vivo, which may counteract the direct effects of FSK on osteoblasts. For instance, interleukin-6 (IL-6), expressed in chondrocytes, was reported to negatively regulate osteoblast differentiation (22) and positively promote osteoclast differentiation and formation (23). Our data showed that IL-6 was strongly expressed in mice chondrocytes (fig. S10A). Furthermore, we found that both mRNA and protein expression of IL-6 in chondrocytes was increased when treated by FSK (fig. S10, B and C). Therefore, our data indicated that PTH, but not FSK, could rescue the body length and bone mass phenotype of Gpr126 loss in the osteoblast lineage not only in vitro but also in vivo.

**DISCUSSION**

Previous genome-wide association studies have found that variations at the GPR126 locus were strongly associated with shortened human body height (4). However, the mechanism has not been conclusively determined. Here, we have identified that Gpr126 in the osteoblast lineage, but not in osteoclasts and chondrocytes, is a critical regulator.
of mouse body length and bone mass. Osteoblast lineage–specific Gpr126 deletion resulted in impaired mouse embryonic bone formation and reduced postnatal bone mass by regulating osteoblast differentiation and ossification. The effects of Gpr126 on osteoblast differentiation and bone formation could be mediated primarily through elevation of intracellular cAMP levels to induce phosphorylation of CREB, accompanied by increasing activity and expression of the osteoblast differentiation marker gene ALP as well as Ocn expression. Furthermore, we found that COLIV was an activating ligand of osteoblast differentiation marker gene ALP as well as Ocn expression. Moreover, we found that COLIV was an activating ligand of Gpr126, resulting in osteoblast differentiation and mineralization. Furthermore, the reduction of body length and bone mass caused by loss of Gpr126 in osteoblasts could be partially restored by PTH treatment in vivo. All our data demonstrated that Gpr126 regulated body height by modulating osteoblast differentiation and ossification.

In our study, we found that the body length shortening phenotype was only observed in the osteoblast lineage conditional Gpr126 deletion mice, but not in osteoclast- or chondrocyte-specific deletion mice. Furthermore, the body length shortening began during embryonic development. The data suggested that Gpr126 regulated body length by affecting osteoblast development. Both osteoblasts and chondrocytes play an important role during embryonic skeletal development, in which most of the bone formation occurs by endochondral ossification (24). Previous research reported that the idiopathic scoliosis and PE induced by cartilage-specific Gpr126 deletion in mice was not through the classical cAMP pathway but by up-regulating the expression of Gal3st4, the gene encoding galactose-3-O-sulfotransferase (8). Our study showed that idiopathic scoliosis and PE did not occur in osteoblast CKO mice. Moreover, Gpr126 regulated bone formation through the classical cAMP-CREB signaling pathway in osteoblast lineage cells. Together, all the results suggest that Gpr126 activates different signaling pathways in specific cell types.

Both COLIV and Laminin-211 have been reported as activating ligands for GPR126 (13, 14). COLIV, a major constituent of the basement membrane, specifically binds to the extracellular N-terminal region of Gpr126 containing the CUB and pentraxin domains and activates Gpr126 signaling pathway in osteoblast lineage cells. Together, the extracellular ligands, COLIV and Laminin-211, might act in concert to induce osteoblast differentiation and mineralization (20).

In our study, we demonstrated that Gpr126 regulates bone height by modulating osteoblast differentiation and ossification. Moreover, we found that COLIV was an activating ligand of Gpr126, resulting in osteoblast differentiation and mineralization. Furthermore, the reduction of body length and bone mass caused by loss of Gpr126 in osteoblasts could be partially restored by PTH treatment in vivo. All our data demonstrated that Gpr126 regulated body height by modulating osteoblast differentiation and ossification.

In our study, we found that the body length shortening phenotype was only observed in the osteoblast lineage conditional Gpr126 deletion mice, but not in osteoclast- or chondrocyte-specific deletion mice. Furthermore, the body length shortening began during embryonic development. The data suggested that Gpr126 regulated body length by affecting osteoblast development. Both osteoblasts and chondrocytes play an important role during embryonic skeletal development, in which most of the bone formation occurs by endochondral ossification (24). Previous research reported that the idiopathic scoliosis and PE induced by cartilage-specific Gpr126 deletion in mice was not through the classical cAMP pathway but by up-regulating the expression of Gal3st4, the gene encoding galactose-3-O-sulfotransferase (8). Our study showed that idiopathic scoliosis and PE did not occur in osteoblast CKO mice. Moreover, Gpr126 regulated bone formation through the classical cAMP-CREB signaling pathway in osteoblast lineage cells. Together, all the results suggest that Gpr126 activates different signaling pathways in specific cell types.

Both COLIV and Laminin-211 have been reported as activating ligands for GPR126 (13, 14). COLIV, a major constituent of the basement membrane, specifically binds to the extracellular N-terminal region of Gpr126 containing the CUB and pentraxin domains and activates Gpr126 signaling pathway in osteoblast lineage cells. Together, the extracellular ligands, COLIV and Laminin-211, might act in concert to induce osteoblast differentiation and mineralization (20).
Fig. 4. *Gpr126* regulates osteoblast differentiation and function through the cAMP-CREB signaling pathway. (A) Intracellular cAMP level was decreased in *Gpr126* deletion osteoblasts. BMSCs were isolated from 1-month-old *Osx-Cre;Gpr126<sup>fl/fl</sup>* mice and Ctrl littermates and differentiated into osteoblasts. The cells were harvested and subjected to the cAMP enzyme-linked immunosorbent assay (ELISA) assay at day 7 of differentiation. **P < 0.01, n = 3.** (B) Western blot analysis of the p-CREB, CREB, and OCN levels in BMSCs from indicated mice after 14 days of osteoblast differentiation. (C) Intracellular cAMP level was restored in *Gpr126* deletion osteoblasts when treated with FSK. BMSCs were isolated from 1-month-old *Osx-Cre;Gpr126<sup>fl/fl</sup>* mice and Ctrl littermates and differentiated into osteoblasts. The cells were treated with 10 μM FSK or vehicle control for 14 days, harvested, and subjected to the cAMP ELISA assay at day 14 of differentiation. **P < 0.01, ***P < 0.001, n = 3.** (D) ALP enzyme activity (N = 5), ALP mRNA expression (n = 2), and OCN mRNA expression (n = 2) were restored in *Gpr126* deletion osteoblasts treated with 1 μM FSK. The cells were harvested and subjected to ALP enzyme activity assay (at day 14) or real-time PCR assay (ALP at day 7 and OCN at day 14). **P < 0.01, ***P < 0.001.** (E) Osteoblast differentiation and mineralization were rescued in *Gpr126* deletion osteoblasts when treated with FSK. BMSCs were isolated from 1-month-old *Osx-Cre;Gpr126<sup>fl/fl</sup>* mice and Ctrl littermates and differentiated into osteoblasts. ALP staining, von Kossa staining, and Alizarin red staining of BMSCs were performed after 7, 14, and 21 days of differentiation, respectively, while treated with or without 10 μM FSK. Scale bars, 5 mm. (F) ALP enzyme activity (N = 5), Alp mRNA expression (n = 2), and Ocn mRNA expression (n = 2) were restored in *Gpr126* deletion osteoblasts treated with PTH(1–34). The cells were harvested and subjected to ALP enzyme activity assay (at day 14) or real-time PCR assay (Alp at day 7 and Ocn at day 14). **P < 0.01, ***P < 0.001.** (G) Osteoblast differentiation and mineralization were rescued in *Gpr126* deletion osteoblasts when treated with PTH(1–34). BMSCs were isolated from 1-month-old *Osx-Cre;Gpr126<sup>fl/fl</sup>* mice and Ctrl littermates and differentiated into osteoblasts. ALP staining, von Kossa staining, and Alizarin red staining of BMSCs were performed after 7, 14, and 21 days of differentiation, respectively, while treated with or without PTH(1–34) (80 μg/kg). Scale bars, 5 mm.
and Lamc1 genes, respectively. It has been reported in zebrafish that Laminin-211 is a previously unidentified ligand for GPR126 to regulate terminal differentiation and myelination by ensuring appropriate levels of cAMP for a given stage of Schwann cell development (14). Therefore, it is reasonable to speculate that different laminin isoforms or subunits may have varying functions in different cell types. We found that stimulation of osteoblasts with COLIV promoted osteoblast differentiation and function and increased the cAMP level, while it had little effect in Gpr126 KO osteoblasts. However, Laminin-211 had no notable effect on osteoblast differentiation and the intracellular cAMP level in both Gpr126 KO and control osteoblasts. Our results raise the possibility of Gpr126 regulation by different agonists in a cell type–specific manner.

Our results demonstrated that two cAMP agonists, FSK and PTH(1–34), could rescue the reduction of osteoblast differentiation and mineralization induced by Gpr126 deletion in vitro. However, only PTH(1–34), but not FSK, rescued the body length and bone mass phenotype of osteoblast–specific Gpr126 deletion mice in vivo. This difference could be explained by an effect of FSK on the microenvironment. The dietary supplement FSK, which is widely used for weight loss (30) and cardiovascular diseases (31), stimulates IL-6 expression in chondrocytes (32), and IL-6 was reported to negatively regulate osteoblast differentiation (22) and positively promote osteoclast differentiation and formation (23). Furthermore, it has been previously reported that IL-6 overexpression leads to body length shortening and bone mass decrease by reducing osteoblast differentiation and increasing osteoclast number and activity in vivo (33). Our data showed that both mRNA and protein expression of IL-6 in chondrocytes was increased in a dose-dependent manner with FSK stimulation, which confirmed our hypothesis. A similar mechanism could function through regulation of glucocorticoids. FSK stimulates glucocorticoid production in the adrenal cortex by increasing cAMP (34), and glucocorticoids could negatively regulate osteoblast proliferation and differentiation (35). A bone mass decrease was found in children after long-term glucocorticoid treatment (36). Therefore, FSK may have had only limited effects on the body length and bone mass phenotype in Gpr126 deletion mice due to microenvironmental factors including IL-6 expression induced by FSK, offsetting the positive effect of FSK on osteoblasts in vivo. PTH(1–34) is a clinically used osteoporosis drug that functions by stimulating osteoblast proliferation (37), increasing osteoblast activity (38), and protecting osteoblasts from apoptosis (39) by directly binding to its receptor PTH1R (40). All our results suggested that it could be used to counteract the shortened human height caused by GPR126 mutation.

In summary, this study suggests that loss of Gpr126 in osteoblasts could delay osteoblast differentiation and bone formation, resulting in shortened body length and bone mass decrease in mice. Gpr126 signals through the cAMP-CREB signaling pathway in osteoblasts, with COLIV as a ligand activating Gpr126 to positively regulate osteoblast differentiation and bone formation. Last, PTH(1–34) may be worth studying as a potential drug to treat the shortened human height or loss of bone mass caused by Gpr126 mutation.
Fig. 6. The reduction of body length, bone mass, and bone strength in Osx-Cre;Gpr126^{fl/fl} mice was partly rescued by PTH treatment. Osx-Cre;Gpr126^{fl/fl} (CKO) mice and Ctrl littermates (n = 6 mice per group) were injected daily with PBS or PTH(1–34) (80 µg/kg) from P5 to P30. The mice were then sacrificed for body length, bone length, bone mass, and bone strength analysis. (A and B) Representative images of Osx-Cre;Gpr126^{fl/fl} (CKO) mice and Ctrl littermates treated with PBS or PTH (1–34) (80 µg/kg) (A). The body length was measured (B). Scale bars, 2 cm. *P < 0.05; **P < 0.01. n = 6. (C and D) Representative femur bone images of Osx-Cre;Gpr126^{fl/fl} (CKO) mice and Ctrl littermates treated with or without PTH (1–34) (80 µg/kg) (C). The femur bone length was measured (D). Scale bars, 2 cm. *P < 0.05. n = 6. (E and F) Bone mass was restored in Osx-Cre;Gpr126^{fl/fl} mice when treated with PTH. Representative μCT images of femurs from 1-month-old Osx-Cre;Gpr126^{fl/fl} mice and Ctrl littermates treated with PTH (1–34). The proximal femur (top) and trabecular bone of the femur metaphysis (bottom) are presented (E). Quantitative μCT analysis of femoral trabecular bone parameters (F). Scale bars, 500 µm (E, top) and 200 µm (E, bottom). *P < 0.05; **P < 0.01. n = 6. (G) Maximal loading of humeral diaphysis from 1-month-old mice by three-point bending assay. *P < 0.05; **P < 0.01. n = 6. Photo credit: Liang He, East China Normal University.
We plated BMSCs at a density of $1 \times 10^5$ cells per well in 24-well plates and expanded them in growth medium for 3 days. We induced osteoblast differentiation by culturing in differentiation culture medium. At days 7, 14, and 21 after inducing osteoblast differentiation, cells were fixed with 4% paraformaldehyde for 15 min and 0.1% Triton X-100 for 10 min and then stained with ALP detection solution (Sigma, N5000; F3381). 2.5% silver nitrate solution (Energy Chemical, 7761-88-8), or 1% Alizarin red S (Sigma, A5533-25G) for ALP, Alizarin red S, and von Kossa staining, respectively, using standard protocols.

### ALP assay
After removing the medium, 24-well plates were washed with phosphate-buffered saline (PBS), and then 0.1% Triton X-100 buffer was added. Cells were frozen and thawed three times, and then incubated at 37°C for 30 min in substrate buffer (Sigma, N7653-100ML). The reaction was then terminated with 3 N NaOH. The optical density of the solution was determined at 405 nm. The ALP activity in each well was divided by the total protein in each well.

### Western blot analysis
The BMSCs were cultured 14 days in differentiation culture medium, harvested, and lysed using radioimmunoprecipitation assay (RIPA) lysis buffer containing a protease inhibitor cocktail (Roche) and phosphatase inhibitors (Roche) on ice. The insoluble material was pelleted by centrifugation (12,000 rpm, 10 min, 4°C), and the supernatants were collected and frozen at −80°C. Total protein concentration was measured using a bicinchoninic acid protein assay (Thermo Scientific). Equivalent amounts of cell lysates were separated on a 9% SDS–polyacrylamide gel electrophoresis gel and transferred to 0.22-μm polyvinylidene difluoride membranes (Whatman). The membranes were blocked with 5% bovine serum albumin and incubated with primary antibodies directed against CREB (Cell Signaling Technology (CST), Danvers, MA; 9197), p-CREB (CST 9198), OCN (Abcam, Cambridge, MA; ab93876), or β-actin (CST, 3700) overnight at 4°C, and then incubated with horseradish peroxidase (HRP)–conjugated secondary antibodies (LI-COR, 926-32211/926-32210). The protein bands were visualized with Immun-Star Western C (LI-COR, USA).

### Real-time PCR
BMSCs were isolated from 4-week-old mice, and total RNA was extracted using TRIzol reagent (Takara, 9109) from cells cultured for 0, 7, or 14 days in differentiation culture medium. The RNA was reverse-transcribed into cDNA using HiScript II Q RT SuperMix (Vazyme, R222-01), and real-time PCR analysis was performed using a real-time PCR system (Thermo Fisher Scientific, Singapore) with Hieff qPCR SYBR Green Master Mix (Low Rox Plus) (YEASEN, 11202ES03). We used predesigned real-time PCR assays from Applied Biosystems for the analysis of ALP and OCN. The PCR primer sequences used were 5′-GTACGCCAACAGCTGCTG-3′ (forward) and 5′-GTCATACTCTGCTGCTG-3′ (reverse) for β-actin, 5′-TCCTGACAAAAACCTCAAGG-3′ (forward) and 5′-TCCTGACGAGCTGCTG-3′ (reverse) for ALP, 5′-CTCACAGTGCCAAGGCA-3′ (forward) and 5′-CAAGGTAGC-GCCGAGTC-3′ (reverse) for OCN, 5′-CCAAAGTTGGCAAT-3′ (forward) and 5′-CTTGGGCTGGCCAGATT-3′ (reverse) for COL1, 5′-TGAGTATGAAAGCAAGGCCAG-3′ (forward) and 5′-CTTGGGCTGGCCAGATT-3′ (reverse) for COL1.
The maximum load (N) was recorded. Measurement data were collected from the load-deformation curves. A point bending test. Two end support points and one central loading point were determined by the CT number. The femur sample area selected for scanning was 0.7 mm below the growth plate. The trabecular bone parameters of the femur were calculated using CTan software (Bruker microCT). The three-dimensional reconstruction images were produced with CTVOL (Bruker microCT). The bone range was reflected with CT numbers of air (1000 HU) and water (0 HU) were used to calibrate the image values in Hounsfield units. The mean value was determined by the CT number. The femur sample area selected for scanning was 0.7 mm below the growth plate.

**Three-point bending test**

To measure the bone strength of the humerus, the small animal bone strength test instrument (YL5-16A, Corp., Yanyi Jinan, P.R. China) was used to perform the three-point bending test. Immediately after dissection, the fresh humerus was examined using the three-point bending test. Two end support points and one central loading point were used for the three-point bending test. The biomechanical measurement data were collected from the load-deformation curves. The maximum load (N) was recorded.

**Histology and in situ hybridization**

Histomorphometry was performed on plastic-embedded tissues using standard protocols. Calcein double labeling was performed by injecting mice with calcein (30 mg/kg) on P30 and P40. Mice were sacrificed on P47, and bones were fixed in 10% buffered formalin and embedded in methyl methacrylate. Bone dynamic histomorphometric analyses for BFR/BS (bone formation rate per bone surface) and MAR (mineral apposition rate) as well as bone static histomorphometric analyses for Ob.S/BS (osteoblast surface per bone surface), Os/BS (osteoid per bone surface), and O.Th (osteoid thickness) were made using the OsteoMeasure Histomorphometry System (OsteoMetrics, Decatur, GA, USA). The bone histomorphometric parameters were calculated and expressed according to the standardized nomenclature for bone histomorphometry. Digoxigenin (DIG)—labeled antisense and sense probes were produced using the DIG Nucleic Acid Detection Kit (Roche) according to the manufacturer’s directions. To examine osteoclast parameters in vivo, the femurs from 8-week-old mice were fixed in 4% paraformaldehyde overnight at 4°C and decalcified in 9% EDTA (pH 7.4) for 7 days before embedding in paraffin and then staining for TRAP. Osteoclast surface/bone surface (Oc.S/BS), the number of osteoclasts/bone perimeter (N.Oc/B.Pm), and the eroded surface/bone surface (ES/BS) were analyzed with the OsteoMeasure Analysis System (OsteoMetrics, Decatur, GA, USA).

**Immunofluorescence**

The femur tissue sections from E18.5 mice were incubated with Anti-Collagen X antibody (Abcam, ab58632) overnight followed by secondary antibodies (Sigma, T8072) for 90 min. Images were captured on a microscope (Olympus, BX53F).

**Statistical analysis**

Data are represented as mean ± SD for absolute values, as indicated in the vertical axis legend of the figures. The statistical significance of differential findings between CKO and Ctrl mice was calculated by SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) using the unpaired two-tailed Student’s t test, and one-way analysis of variance (ANOVA) was used to examine the effects of treatment with FSK, PTH, COLIV, and Laminin-211. Significance was P < 0.05.

**SUPPLEMENTARY MATERIALS**

Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/12/eaaz0368/DC1. Fig. S1. Strategy of targeting the Gpr126loxP allele. Fig. S2. The expression of Gpr126 in different bone cells and genotyping. Fig. S3. Body length and embryonic bone formation in Lysm-Cre;Gpr126loxP and Col2-Cre;Gpr126loxP was not different compared to their control littermates. Fig. S4. Deletion of Gpr126 in osteoblast lineage (Osx-Cre) had little effect on osteoclastogenesis and osteoclast activity in vivo and in vitro. Fig. S5. Deletion of Gpr126 in osteoblast lineage (Osx-Cre) had little effect on chondrocyte differentiation and hypertrophy. Fig. S6. The expression of COLIV and Laminin-211 was determined by in situ hybridization and osteoclast activity in vivo and in vitro. Fig. S7. The selective Wnt/β-catenin inhibitor KY1797X had little effect on COLIV-induced osteoblast differentiation and mineralization. Fig. S8. The selective Wnt/β-catenin inhibitor KY1797X had little effect on osteoclastogenesis and osteoclast activity in vivo and in vitro. Fig. S9. Administration of FSK had little effect on bone length, femur bone length, bone mass, and bone strength of Osx-Cre;Gpr126loxP mice. Fig. S10. The expression of IL-6 was increased in chondrocytes treated by FSK.
J. Gao, X. Li, Y. Zhang, H. Wang. Endochondral ossification in hindlimbs during Bmp4 gain-of-function and morph mimics: A model of studying skeletal development in vertebrates. Dev. Dynam. 247, 1121–1134 (2018).

L. Li, J. Zhang. M.-A. Akimoto. Inhibition of mmp13a during zebrafish fin regeneration disrupts fin growth, osteoblast differentiation, and Laminin organization. Dev. Dynam. 249, 187–198 (2020).

N. Uehara, A. Kukita, Y. Kiyomoto-Nakamura, T. Yamaza, H. Yasuda, T. Kukita. Osteoblast-derived Laminin-332 is a novel negative regulator of osteoclastogenesis in bone microenvironments. Lab. Invest. 97, 1235–1244 (2017).

Z. Yang, Y. Xi, K. Lai, Y. Wang, H. Yang. Laminin-521 promotes rat bone marrow mesenchymal stem cell formation on light-induced cell sheet technology. Biomed. Res. Int. 2017, 9475473 (2017).

C. Beaufils, D. Farlay, I. Machuca-Gayet, A. Fassier, M. Zener, C. Freychet, E. Bonneyele, A. Bertholet-Thomas, B. Ranchin, J. Bacchetta. Skeletal impairment in Pierson syndrome: Is there a role for laminin2J in bone physiology? Bone 106, 187–193 (2018).

S. Viale-Bouroncle, M. Gosses, C. Morosczek, Laminin regulates the osteogenic differentiation of dental follicle cells via integrin-β2-β1 and the activation of the FAK/ERK signaling pathway. Cell Tissue Res. 357, 345–354 (2014).

A. Rios-Hoyo, G. Gutiérrez-Salmerán. New dietary supplements for obesity: What we currently know. Curr. Opin. 5, 262–270 (2016).

V. García-Morales, M. Luaces-Reguera, M. Campos-Toimil, The cAMP effectors PKA and Epac activate endothelial NO synthase through PKA/Akt pathway in human endothelial cells. Biochem. Pharmacol. 145, 94–101 (2017).

P. Wang, F. Zhu, K. Konstantopoulou, Prostaglandin EI induces interleukin-6 expression in human chondrocytes via cAMP/protein kinase A and phosphatidylinositol 3-kinase-dependent NF-κB activation. Am. J. Physiol. Cell Physiol. 298, C1445–C1456 (2010).

F. De Benedetti, N. Rucci, A. D. Fattore, B. Peruzzi, R. Paro, M. Longo, M. Vivarelli, F. Muratori, S. Berni, P. Ballanti, S. Ferrari, A. Teti. Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54, 3551–3563 (2006).

A. N. Evans, Y. Liu, R. MacGregor, V. Huang, A. Aguilar. Regulation of hypocalcemic corticotropin-releasing hormone transcription by elevated glucocorticoids. Mol. Endocrinol. 27, 1796–1807 (2013).

T. Tomori. Glucocorticoid signaling and bone biology. Horm. Metab. Res. 48, 755–763 (2016).

H. W. Park, S. Tae, W. Yang, H. W. Kelly, S. C. Kaste, C. H. Pui, M. V. Relling, K. G. Tantisira. A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment. Pharmacogenomics J. 17, 180–185 (2017).

K. Zhang, M. Wang, Y. Li, C. Li, S. Tang, X. Qu, N. Feng, Y. Wu, The PERK-EIF2ζ-AFT4 signaling branch regulates osteoblast differentiation and proliferation by PTH. Am. J. Physiol. Endocrinol. Metabol. 316, E590–E604 (2019).

A. Iwata, M. Kanayama, F. Oha, T. Hashimoto, N. Isawa. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fractures: A retrospective comparative study. BMC Musculoskelet. Disord. 18, 148 (2017).

R. Liu, Q. Wang, Y. Han, J. Li, X.-J. Yang, D. Miao. Parathyroid hormone administration improves bone marrow microenvironment and partially reverses haematopoietic defects in Bm1-null mice. PLoS ONE 9, e83964 (2014).

D. H. Balani, N. Ono, H. M. Kronenberg, Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J. Clin. Invest. 127, 3327–3338 (2017).

Acknowledgments: Funding: This work was supported by grants from the National Key Research and Development Program of China (2018YFC1105102 to J.L., 2018YFA0700701 to M.L., and 2018YFC0201500 to J.S.), the National Natural Science Foundation of China (8111305339, 81722020, and 91749127 to J.L.; 81630083 to M.L.; and 91749204 to J.S.), the Innovation Program of the Shanghai Municipal Education Commission (2017-01-07-00-05-E00011 to M.L.), the Shanghai Science and Technology Committee (201707010001), and the Shanghai Science and Technology Committee (201712010001 to M.L.), and the Shanghai Health and Family Planning Commission (201712010001).
Regulation of body length and bone mass by Gpr126/Adgrg6

Peng Sun, Liang He, Kunhang Jia, Zhiying Yue, Shichang Li, Yunyun Jin, Zhenxi Li, Stefan Siwko, Feng Xue, Jiacan Su,
Mingyao Liu and Jian Luo

Sci Adv 6 (12), eaaz0368.
DOI: 10.1126/sciadv.aaz0368